Martin Worley Group’s KalVista Pharmaceuticals KALV Stock Holding History

Martin Worley Group’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$115K	Hold	10,168	–	–	0.06%	90
2025 Q1	$117K	Hold	10,168	–	–	0.07%	81
2024 Q4	$86.1K	Buy	+10,168	New	+$105K	0.05%	85

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Capital World Investors

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Silverarc Capital Management Boston, Massachusetts $849M AUM 470.8% 1-Year Est. Return